Home  >  News
you can get e-magazine links on WhatsApp.Click here
Pioma_Lactic
Biotechnology + Font Resize -

Sanofi to focus its Covid-19 development efforts on the recombinant vaccine candidate

Paris
Thursday, September 30, 2021, 14:00 Hrs  [IST]

Sanofi announced recent positive interim results of its mRNA-based Covid-19 vaccine candidate phase 1/2 study confirm the company’s platform robust capabilities and strategy in mRNA.

Taking into account public health needs and given sufficient mRNA Covid-19 vaccines supply can be expected going forward, Sanofi has decided not to pursue the development of its Covid-19 mRNA candidate into a phase 3 clinical study and will focus on completing the final development steps of its Covid-19 recombinant vaccine, developed in partnership with GSK.

Building on its positive results, the company will focus its mRNA resources in its newly created mRNA Center of Excellence to address future pandemics and other infectious diseases and therapeutics where there is a strong unmet need.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |